The urgent need to recover MHC class I in cancers for effective immunotherapy

Current Opinion in Immunology

Volumn 39, Issue , 2016, Pages 44-51

  Garrido, Federico ^a,b,c   Aptsiauri, Natalia ^b,c   Doorduijn, Elien M ^d   Garcia Lora, Angel M ^b,c   van Hall, Thorbald ^d  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c Instituto De Investigación Biosanitaria de Granada Ibs GRANADA   (Spain)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; HLA ANTIGEN CLASS 1;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; HUMAN; NATURAL KILLER CELL; NONHUMAN; REVIEW; TUMOR DORMANCY; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR REJECTION; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS;

ANIMALS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84955463999     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2015.12.007     Document Type: Review

References (70)

1. Rosenberg S.A., Lotze M.T., Muul L.M. A progress report on the treatment of 157 patients with advance cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987, 316:889-897.
2. Morales A., Eidinger D., Bruce A.W. Intracavitary Bacillus Calmette Guerin in the treatment of superficial bladder tumors. J Urol 1976, 116:180-183.
3. Askeland E.J., Newton M.R., O'Donnell M.A., Luo Y. Bladder cancer immunotherapy: BCG and beyond. Adv Urol 2012, article 181987.
4. Marchand M., Van Baren N., Weynan P., Brichard V., Dreno B., Tessier M.-H., Rankin E., Parmiani G., Arienti F., Humblet Y., et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999, 80:219-230.
5. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., Shadendorf D. Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells. Nat Med 1998, 4:328-332.
6. Rosenberg S.A., Sherry R.M., Morton K.E., Scharfman W.J., Yang J.C., Topalian S.L., Royal R.E., Kammula U., Restifo N.P., Hughes M.S., et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005, 175:6169-6176.
7. Festenstein H., Garrido F. MHC antigens and malignancy. Nature 1986, 322:502-503.
8. Garrido F., Cabrera T., Concha A., Glew S., Ruiz-Cabello F., Stern P.L. Natural history of HLA expression during tumor development. Immunol Today 1993, 14:491-499.
9. Garrido F., Ruiz-Cabello F., Cabrera T., Perez-Villar J.J., Lopez-Botet M., Duggan-Keen M., Stern P.L. Implications for immunosurveillance of altered. HLA class I phenotypes in human tumors. Immunol Today 1997, 18:89-95.
10. Marincola F.M., Jafee E.M., Hicklin D.J., Ferrone S. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000, 74:181-273.
11. Garrido F., Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001, 83:117-158.
12. Seliger B., Cabrera T., Garrido F., Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002, 12:3-13.
13. Cabrera T., Lopez-Nevot M.A., Gaforio J.J., Ruiz-Cabello F., Garrido F. Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 2003, 52:1-9.
14. Carretero R., Wang E., Rodriguez A.I., Reinboth J., Ascierto M.L., Engle A.M., Liu H., Camacho F., Marincola F.M., Garrido F., Cabrera T. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer 2012, 131:387-395.
15. Romero I., Garrido C., Algarra I., Collado A., Garrido F., Garcia-Lora A.M. T lymphocytes restrain spontaneous metastases in permanent dormancy. Cancer Res 2014, 74:1958-1968.
16. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., Smyth M.J., Schreiber R.D. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450:903-907.
17. Fisher R., Puztai I., Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 2013, 108:479-485.
18. Gerlinger M., Rowan A.J., Horswell S. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
19. Garrido F., Romero I., Aptsiauri N., Garcia-Lora A.M. Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype. Int J Cancer 2016, 138:271-280.
20. Carretero R., Romero J.M., Ruiz-Cabello F., Maleno I., Rodriguez F., Camacho F.M., Real L.M., Garrido F., Cabrera T. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 2008, 60:439-447.
21. del Campo A.B., Kyte J.A., Carretero J., Zinchencko S., Méndez R., González-Aseguinolaza G., RuizCabello F., Aamdal S., Gaudernack G., et al. Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma. Int J Cancer 2014, 134:102-113.
22. Garcia-Lora A., Algarra I., Gafori J.J., Ruiz-Cabello F., Garrido F. Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. Int J Cancer 2001, 91:109-119.
23. Garcia-Lora A., Martinez M., Algarra I., Gaforio J.J., Garrido F. MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components. Int J Cancer 2003, 106:521-527.
24. Garrido C., Romero I., Berruguilla E., Cancela B., Algarra I., Collado A., Garcia-Lora A.M., Garrido F. Immunotherapy eradicates metastases with reversible defects in MHC class I expression. Cancer Immunol Immunother 2011, 60:1257-1268.
25. Romero P., Coulie P. Adaptive T-cell immunity and tumor antigen recognition. Tumor Immunology and Immunotherapy 2014, 1-14. Oxford University Press. R.C. Rees (Ed.).
26. Wang E., Worschech A., Marincola F.M. The immunological constant of rejection. Trends Immunol 2008, 29:256-262.
27. Ryschich E., Nötzel T., Hinz U., Autschbach F., Ferguson J., Simon I., Weitz J., Fröhlich B., Klar E., Büchler M.W., Schmidt J. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma. Clin Cancer Res 2005, 11(Pt 1):498-504.
28. Pages F., Kirilovsky A., Mlecnik B., Asslaber M., Tosolini M., Bindea G., Lagorce C., Wind P., Marliot F., Bruneval P., et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009, 27:5944-5951.
29. Garrido F., Cabrera T., Accola R.S., Bensa J.C., Wodmer W., Dohr G., Drenou B., Drouet M., Fauchet R., Ferrara G.B., et al. HLA and cancer. HLA Genetic diversity of HLA. Functional and Medical Implications 1997, vol. 1:445-452. EDK.
30. Rusakiewicz S., Semeraro M., Sarabi M., Desbois M., Locher C., Mendez R., Vimond N., Concha A., Garrido F., Isambert N., et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res 2013, 73:3499-3510.
31. Kvistborg P., Philips D., Kelderman S., Hageman L., Ottensmeier C., Joseph-Pietras D., Welters M., van de Burg S., Kapiteijn E., Michielin O., et al. Anti CTL-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med 2014, 6:1-9.
32. Robert L., Tsoi J., Wang X., Emerson R., Homet B., Chodon T., Mok S., Huang R.R., Cochran A., Comin-Anduix B., et al. CTLA4 blockade broadens the peripheral T cell receptor repertoire. Clin Cancer Res 2014, 20:2424-2432.
33. Buferne M., Chasson L., Grange M., Mas A., Arnoux F., Bertuzzi M., Naquet P., Leserman L., Schmitt-Verhulst A.M., Auphan-Anezin N. IFN-γ producing CD8+ cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas. Oncoimmunology 2015, 4:e974759.
34. Corbiere V., Chapiro J., Stroobant V., Ma W., Lurquin C. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res 2011, 71:1253-1262.
35. Garrido F., Klein E. MHC antigen expression. I. Human tumors. Seminars in Cancer Biology 1991, vol 2-1:1-2. W.B. Saunders Scientific Publications.
36. Koopman L.A., Corver W.E., Van del Slik A.R., Giphart M.J., Fleuren G.J. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 2000, 191:961-976.
37. Murchison E.P., Schulz-Trieglaff O.B., Ning Z., Alexandrov L.B., Bauer M.J., Fu B., Hims M., Ding Z., Ivakhno S., Stewart C., et al. Genome sequencing and analysis of the Tasmanian devil and its transmissible cancer. Cell 2012, 148:780-791.
38. Siddle H.V., Kreiss A., Tovar C., Yuen C.K., Cheng Y., Belov K., Swift K., Pearse A.M., Hamede R., Jones M.E., et al. Reversible epigenetic down-regulation of MHC molecules by devil facial tumor disease illustrates immune escape by a contagious cancer. Proc Natl Acad Sci U S A 2013, 110:5103-5108.
39. Woods G.M., Howson L.J., Brown G.K., Tovar C., Kreiss A., Corcoran L.M., Lyons A.B. Immunology of a transmissible cancer spreading among Tasmanian Devils. J Immunol 2015, 195:23-29.
40. Garrido F., Cabrera T., Aptsiauri N: 'Hard' and 'soft' lesions underlying the HLA Class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 2010, 127:249-256.
41. Seliger B. Novel insights into the molecular mechanisms of HLA class I abnormalities. Cancer Immunol Immunother 2012, 61:249-254.
42. Seliger B. B7-H abnormalities in melanoma and clinical relevance. Methods Mol Biol 2014, 1102:367-380.
43. Garrido G., Rabasa A., Garrido C., López A., Chao L., García-Lora A.M., Garrido F., Fernández L.E., Sánchez B. Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms. Oncogene 2014, 33:3129-3139.
44. Lampen M., van Hall T. Strategies to counteract MHC-I defects in tumors. Curr Opin Immunol 2011, 23:293-298.
45. Cozar J.M., Aptsiauri N., Tallada M., Garrido F., Ruiz-Cabello F. Late pulmonary metastases of renal cell carcinoma immediately after post-transplantation immunosuppressive treatment: a case report. J Med Case Rep 2008, 2:111.
46. Romero I., Garrido F., Garcia-Lora A.M. Metastases in immune-mediated dormancy: a new opportunity for targeting cancer. Cancer Res 2014, 74:6750-6757.
47. Romero I., Martinez M., Garrido C., Collado A., Algarra I., Garrido F., Garcia-Lora A.M. The tumor suppressor Fhit positively regulates MHC class I expression on cancer cells. J Pathol 2012, 227:367-379.
48. Símová J1, Polláková V., Indrová M., Mikyšková R., Bieblová J., Stěpánek I., Bubeník J., Reiniš M. Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumors with different MHC class I-expression status. Br J Cancer 2011, 105:1533-1541.
49. Park J., Thomas S., Munster P.N. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. Epigenomics 2015, 7:641-652.
50. Kim K., Skora A.D., Li Z., Liu Q., Tam A.J., Blosser R.L., Diaz L.A., Papadopoulos N., Kinzler K.W., Vogelstein B., et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A 2014, 111:11774-11779.
51. Vlková V., Štěpánek I., Hrušková V., Šenigl F., Mayerová V., Šrámek M., Šímová J., Bieblová J., Indrová M., Hejhal T., et al. Epigenetic regulations in the IFNγ signalling pathway: IFN-γ-mediated MHC class I upregulation on tumor cells is associated with DNA demethylation of antigen-presenting machinery genes. Oncotarget 2014, 5:6923-6935.
52. Aptsiauri N., Garcia-Lora A., Garrido F. 'Hard' and 'soft' loss of MHC class I expression in cancer cells. Tumor Immunology and Immunotherapy 2014, 63-78. Oxford University Press. R.C. Rees (Ed.).
53. Maleno I., Cabrera C.M., Cabrera T., Paco L., Lopez-Nevot M.A., Collado A., Ferron A., Garrido F. Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics 2004, 56:244-253.
54. Kloor M., Michel S., von Knebel Doeberitz M. Immune evasion of microsatellite unstable colorectal cancers. Int J Cancer 2010, 127:1001-1010.
55. Bernal M., Ruiz-Cabello F., Concha A., Paschen A., Garrido F. Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes. Cancer Immunol Immunother 2012, 61:1359-1371.
56. Maleno I., Aptsiauri N., Cabrera T., Gallego A., Paschen A., López-Nevot M.A., Garrido F. Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors. Immunogenetics 2011, 63:65-71.
57. del Campo A., Aptsiauri N., Mendez R., Zinchenko S., Vales A., Paschen A., Ward S., Ruiz-Cabello F., González-Aseguinolaza G., Garrido F. Efficient recovery of HLA class I expression in human tumor cells after beta2-microglobulin gene transfer using adenoviral vector: implications for cancer immunotherapy. Scand J Immunol 2009, 70:125-135.
58. del Campo Ana B., Carretero J., Aptsiauri N., Garrido F. Targeting tumor HLA class I expression to increase tumor immunogenicity. Tissue Antigens 2012, 79:147-154.
59. del Campo A.B., Carretero J., Muñoz J.A., Zinchenko S., Ruiz-Cabello F., González-Aseguinolaza G., Garrido F., Aptsiauri N. Adenovirus expressing β2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition. Cancer Gene Ther 2014, 21:317-332.
60. Ardolino M., Azimi C.S., Iannello A., Trevino T.N., Horan L., Zhang L., Deng W., Ring A.M., Fischer S., Garcia K.C., et al. Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J Clin Invest 2014, 124:4781-4794.
61. Ni J., Miller M., Stojanovic A., Garbi N., Cerwenka A. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med 2012, 209:2351-2365.
62. Yang H., Lan P., Hou Z., Guan Y., Zhang J., Xu W., Tian Z., Zhang C. Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma. Br J Cancer 2015, 112:112-121.
63. Zhu S., Denman C.J., Cobanoglu Z.S., Kiany S., Lau C.C., Gottschalk S.M., Hughes D.P., Kleinerman E.S., Lee D.A. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Pharm Res 2015, 32:779-792.
64. Fiegler N., Textor S., Arnold A., Rölle A., Oehme I., Breuhahn K., Moldenhauer G., Witzens-Harig M., Cerwenka A. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood 2013, 122:684-693.
65. van Hall T., Wolpert E.Z., van Veelen P., Laban S., van der Veer M., Roseboom M., Bres S., Grufman P., de Ru A., Meiring H., et al. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med 2006, 12:417-424.
66. Seidel U.J., Oliveira C.C., Lampen M.H., van Hall T. A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens. Cancer Immunol Immunother 2012, 61:119-125.
67. Oliveira C.C., van Hall T. Importance of TAP-independent processing pathways. Mol Immunol 2013, 55:113-116.
68. Oliveira C.C., van Hall T. Alternative antigen processing for MHC class I: multiple roads lead to Rome. Front Immunol 2015, 6:298.
69. Oliveira CC1, Querido B., Sluijter M., de Groot A.F., van der Zee R., Rabelink M.J., Hoeben R.C., Ossendorp F., van der Burg S.H., van Hall T. New role of signal peptide peptidase to liberate C-terminal peptides for MHC class I presentation. J Immunol 2013, 191:4020-4028.
70. Doorduijn E.M., Sluijter M., Querido B.J., Oliveira C.C., Achour A., Ossendorp F., van der Burg S.H., van Hall T. TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors. J Clin Invest 2016, 126.